Reproductive toxicity testing is a critical component in drug development, providing essential insight into how new pharmaceutical candidates may affect fertility, embryonic development, and offspring health. Early identification of reproductive risks enables optimized compound selection, reduces late-stage attrition, and informs safe dosing strategies. BOC Sciences offers a comprehensive suite of reproductive toxicity services tailored to pharmaceutical pipelines, including fertility function, embryo-fetal development, peri- and postnatal assessments, extended one-generation, and multi-generation studies, as well as rapid in vitro screening. Leveraging advanced analytical platforms, customizable study designs, and a multidisciplinary team of toxicologists and pharmacologists, BOC Sciences delivers precise, actionable reproductive toxicity data to support informed drug development decisions globally.
Covers comprehensive evaluation of male and female reproductive capacity, including gametogenesis, mating success, conception rate, and gamete quality analysis, such as sperm motility and oocyte maturation. At BOC Sciences, we design exposure schedules aligned with reproductive cycles to deliver precise and reproducible fertility data supporting compound screening and mechanism studies.
Focuses on assessing the effects of test substances during the critical embryonic period, examining fetal morphology, organ development, body weight, and malformation incidence. BOC Sciences provides integrated studies in rodents and rabbits, ensuring reliable characterization of developmental outcomes and early identification of potential teratogenic risks.
Evaluates maternal performance, delivery outcomes, lactation behavior, and postnatal growth of offspring through weaning and adolescence. At BOC Sciences, our studies incorporate behavioral, neurological, and immunological endpoints to offer a complete understanding of developmental and functional consequences following perinatal exposure.
Extends assessment beyond parental generation to F1 offspring, enabling a more holistic evaluation of reproductive and developmental endpoints. BOC Sciences applies modular study designs that capture critical life-stage data efficiently, supporting data-driven decision-making for long-term safety and risk assessment.
Monitors reproductive performance and developmental parameters across two or more generations (F0–F1–F2). Our BOC Sciences team provides high-integrity multi-generation models for compounds requiring detailed intergenerational profiling, ensuring comprehensive insight into chronic and hereditary reproductive outcomes.
Offers rapid, cost-effective in vitro and in vivo screening methods including sperm viability, endocrine receptor activity, and early embryotoxicity assays. At BOC Sciences, we employ high-throughput platforms for preliminary hazard identification, enabling efficient compound prioritization prior to full-scale reproductive toxicity studies.
Our team offers tailored study design and rapid results to accelerate your development process.
Our reproductive toxicity testing services accommodate a wide range of sample types to evaluate potential effects on fertility, development, and reproductive health.
Share your compound or product details, and our experts will provide tailored guidance and testing strategies.
We provide a series of in vitro and alternative methods as part of our reproductive toxicity testing services. These approaches are designed for early-stage screening and mechanistic evaluation, offering high throughput, reduced animal usage, and improved predictive reliability.
| Testing Method | Principle / Features | Key Evaluation Endpoints |
| Embryonic Stem Cell Test (EST) | Detects whether a compound inhibits the differentiation of mouse embryonic stem cells into cardiomyocytes. | Differentiation rate, cytotoxicity threshold. |
| Frog Embryo Teratogenesis Assay (FETAX) | Uses Xenopus laevis embryos to evaluate developmental toxicity under controlled exposure conditions. | Embryo survival rate, malformation rate, developmental delay. |
| In Vitro Gamete and Fertilization Tests | Includes Sperm Penetration Assay (SPA), in vitro fertilization (IVF), and embryo culture observation. | Gamete quality, fertilization rate, embryonic growth assessment. |
| Endocrine Disruption Screening | Cell- and molecular-level assays such as Estrogen/Androgen Receptor Binding (ER/AR) and Transactivation Assays (YES/YAS, E-Screen). | Hormone receptor binding activity, pathway response changes. |
| Computational Modeling | Employs graph convolutional networks (GCN) and other machine learning algorithms to predict potential reproductive and developmental toxicity of organic and inorganic compounds. | Predicted toxicity endpoints, probability scores, mechanistic correlation. |
Clients provide sample details and testing objectives. Our scientific consultants evaluate requirements and design a tailored reproductive toxicity strategy.
The team develops study protocols including selection of test models, dose groups, administration routes, and key reproductive endpoints.
Procedures include animal handling, dosing preparation, tissue sampling, and reproductive organ histopathology, with real-time monitoring of experimental parameters and endpoints.
Statistical analysis and evaluation of reproductive toxicity endpoints are performed, results visualized in tables/graphs, and a professional report with scientific interpretation is delivered.
We provide tailored reproductive toxicity testing for innovative biologics and small molecules, including multi-generation in vivo studies and mechanistic in vitro assays. Our solutions help biotech developers evaluate reproductive safety efficiently, supporting informed decisions throughout early R&D stages.
BOC Sciences offers comprehensive reproductive toxicity testing for drug candidates, covering embryo-fetal development, fertility, and pre- and post-natal assessments. Our customized strategies enable pharmaceutical companies to optimize study design and generate reliable safety data rapidly.
We support academic and translational research with flexible reproductive toxicity testing solutions, including mechanistic studies and exploratory in vitro/in vivo assays. Our services help researchers investigate reproductive effects, facilitating deeper understanding of compound safety profiles.
BOC Sciences delivers adaptable reproductive toxicity testing solutions for CROs and research partners, providing study design, protocol optimization, and data analysis. Our services enhance partner efficiency and accuracy, enabling robust reproductive safety evaluations for diverse compound pipelines.
Contact BOC Sciences to access our expert reproductive toxicity services. We provide thorough assessments across multiple endpoints, ensuring high-quality, actionable data to streamline your R&D pipeline and facilitate faster, evidence-based project progression.
We provide integrated reproductive toxicity testing services covering multi-generational studies to ensure broad-spectrum chemical safety evaluation.
Our laboratories employ cutting-edge analytical technologies, enabling detection of subtle toxicological effects across diverse biological matrices.
Our team combines toxicologists, pharmacologists, and data scientists to deliver reliable interpretation and actionable insights from complex datasets.
We provide flexible testing strategies with tailored protocols, enabling efficient evaluation across diverse compound classes and endpoints.
Client Needs: A biotech company developing a small-molecule oncology candidate required an assessment of potential reproductive toxicity to inform preclinical lead selection and minimize downstream attrition.
Challenges: The client needed reliable detection of subtle gonadal changes amid species-specific fertility differences and to achieve reproducible reproductive endpoints across cohorts.
Solution: BOC Sciences designed an integrated reproductive toxicity testing plan, combining multi-generational rodent studies with hormonal profiling, sperm/oocyte quality assessment, and detailed histopathology. Advanced imaging and stereological quantification provided sensitive detection of subtle gonadal changes, while optimized dosing schedules minimized inter-animal variability.
Outcome: Delivered comprehensive reproductive toxicity data with high sensitivity, enabling precise risk evaluation, informed structural optimization, and confident progression of the oncology candidate into subsequent preclinical stages.
Client Needs: A pharmaceutical company focusing on CNS therapies needed reproductive toxicity evaluation to support compound prioritization among several neuroactive candidates.
Challenges: The client faced variability in BBB penetration and endocrine effects, making standard reproductive endpoints unreliable for candidate comparison.
Solution: BOC Sciences implemented a customized reproductive toxicity testing protocol, integrating hormone assays, mating trials, and reproductive organ histopathology. Cross-species comparison and repeated-measures analysis enhanced detection of subtle endocrine disruptions. Automated data capture and high-resolution imaging improved reproducibility and statistical confidence.
Outcome: Produced actionable reproductive toxicity profiles, revealing candidate-specific fertility risks and dose-response relationships, supporting informed lead selection and structural refinement to mitigate reproductive liabilities.
Client Needs: A biopharmaceutical company developing an oral anti-diabetic agent sought to assess long-term reproductive effects across generations to optimize early-stage candidate selection.
Challenges: The client struggled to monitor multi-generational developmental and reproductive endpoints and detect subtle skeletal or organ maturation changes.
Solution: BOC Sciences conducted a structured multi-generational reproductive toxicity study, combining developmental landmark assessment, gametogenesis evaluation, and organ histomorphometry. Continuous biomarker monitoring and automated data integration enabled sensitive detection of intergenerational reproductive effects and minimized variability.
Outcome: Delivered high-resolution reproductive toxicity profiles across two generations, identifying potential developmental susceptibilities and providing guidance for chemical optimization, dose selection, and strategic candidate prioritization.
Reproductive toxicity testing is designed to assess the potential impact of chemicals or drug candidates on the reproductive system and fertility, including effects on organ development, gamete formation, fertilization capacity, and embryo development. Through systematic in vitro and in vivo studies, researchers can identify potential reproductive health risks early, providing a scientific basis for subsequent development or safety evaluation. BOC Sciences offers a mature reproductive toxicity testing platform and can provide comprehensive support for experimental design and data interpretation based on client needs.
Toxicity testing is typically conducted using a combination of in vitro cell models and in vivo animal models to capture responses at different biological levels. Researchers select appropriate dose ranges and exposure durations according to study objectives and evaluate toxic effects using endpoints such as cell proliferation, organ morphology, hormone levels, and embryo development. BOC Sciences provides flexible, customized methodological solutions to ensure scientific rigor and comparability of data.
A reproductive toxicologist focuses on studying the effects of chemicals or drugs on the reproductive system and embryo development. They design experimental protocols, select suitable models, monitor key biological markers, and analyze study data to provide scientific conclusions and risk assessment insights. Involvement of a professional reproductive toxicology team can significantly enhance the reliability of testing and the interpretation of results.
Reproductive toxicity reflects the potential of a substance to affect reproductive function and the health of future generations. It may manifest as organ damage, hormonal imbalances, reduced fertilization rates, or abnormal embryo development. Early identification of these risks allows research teams to optimize compound structures or implement safe usage strategies, thereby reducing uncertainty and potential risks during the development stage.
Reproductive toxicity testing is critical in the development of new materials or drugs, as it not only identifies potential safety concerns but also guides product optimization. Systematic testing enables companies to make informed decisions early in development, avoiding the risk of costly failures later. BOC Sciences has an experienced reproductive toxicity testing team that provides complete technical services from experimental design to data interpretation, enhancing development efficiency.
The reproductive toxicity testing services from BOC Sciences provided highly reliable data with clear interpretation. Their team's thorough experimental design and attention to detail helped us identify subtle reproductive endpoints that were critical for our research strategy.
— Dr. M., Senior Scientist, Pharmaceutical R&D Division
BOC Sciences delivered reproductive toxicity studies with exceptional comprehensiveness. Their systematic approach to study planning and data analysis ensured that all relevant reproductive parameters were captured accurately, supporting our internal decision-making process.
— Dr. K., Head of Preclinical Research, Specialty Biopharma
Working with BOC Sciences for reproductive toxicity testing was extremely valuable due to their expert data interpretation and clear reporting. The insights gained from their detailed evaluation of reproductive endpoints strengthened our mechanistic understanding of test compounds.
— Dr. T., Principal Investigator, Academic Research Institute
The reproductive toxicity testing conducted by BOC Sciences consistently produced high-confidence results. Their meticulous methodology and rigorous data validation allowed us to make informed decisions with minimal ambiguity, significantly supporting our project planning.
— Dr. S., Research Director, Emerging Biotech Startup
